Table 1

Characteristics of 443 adult patients with JIA at point of starting their first TNFi

All JIA patients
Median (IQR) or Number (%)
Gender, female331 (75%)
Age at treatment start, years33 (24–41)
Age at disease onset, years13 (9–15)
Disease duration, years22 (13–31)
Ethnicity; white338 (95%) N=356
On methotrexate257 (58%)
On steroids173 (39%)
Disease pattern
 Systemic onset12 (3%)
 Oligoarticular pattern7 (2%)
 Polyarticular pattern327 (73%)*
 Enthesitis-related arthritis53 (12%)
 Psoriatic arthritis44 (10%)
TNFi at registration
 Etanercept199 (45%)
 Infliximab137 (31%)
 Adalimumab101 (23%)
 Certolizumab6 (1%)
Disease activity
 28 tender joint count14 (8–20) N=401
 28 swollen joint count10 (5–15) N=402
 Patient global assessment (100 mm VAS)75 (65–85) N=405
 ESR, mm/hour35 (19–56) N=402
 CRP, mg/L30 (10–52) N=210
 DAS286.2 (5.5–7.0) N=405
 HAQ (0–3)1.9 (1.5–2.4) N=403
Total comorbidities†N=423
 None227 (54%)
 1131 (31%)
 ≥265 (15%)
Smoking statusN=438
 Current smoker101 (23%)
 Previous smoker79 (18%)
 Never smoked258 (59%)
  • *150 patients with polyarticular pattern were rheumatoid factor positive (46% of polyarticular pattern, 33% of cohort overall).

  • †Comorbidities include; hypertension, angina, myocardial infarction, stroke, epilepsy, asthma, chronic bronchitis/emphysema, peptic ulcer, liver disease, renal disease, tuberculosis, demyelination, diabetes, hyperthyroidism, depression, cancer.

  • Presenting number (%), or median (IQR), including number with available data (N) where applicable.

  • CRP, C reactive protein; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; JIA, juvenile idiopathic arthritis; TNFi, tumour necrosis factor inhibitor; VAS, visual analog scale.